Literature DB >> 23199705

Role of CB1 and CB2 cannabinoid receptors in the development of joint pain induced by monosodium iodoacetate.

Carmen La Porta1, Simona Andreea Bura, Auxiliadora Aracil-Fernández, Jorge Manzanares, Rafael Maldonado.   

Abstract

Joint pain is a common clinical problem for which both inflammatory and degenerative joint diseases are major causes. The purpose of this study was to investigate the role of CB1 and CB2 cannabinoid receptors in the behavioral, histological, and neurochemical alterations associated with joint pain. The murine model of monosodium iodoacetate (MIA) was used to induce joint pain in knockout mice for CB1 (CB1KO) and CB2 cannabinoid receptors (CB2KO) and transgenic mice overexpressing CB2 receptors (CB2xP). In addition, we evaluated the changes induced by MIA in gene expression of CB1 and CB2 cannabinoid receptors and μ-, δ- and κ-opioid receptors in the lumbar spinal cord of these mice. Wild-type mice, as well as CB1KO, CB2KO, and CB2xP mice, developed mechanical allodynia in the ipsilateral paw after MIA intra-articular injection. CB1KO and CB2KO demonstrated similar levels of mechanical allodynia of that observed in wild-type mice in the ipsilateral paw, whereas allodynia was significantly attenuated in CB2xP. Interestingly, CB2KO displayed a contralateral mirror image of pain developing mechanical allodynia also in the contralateral paw. All mouse lines developed similar histological changes after MIA intra-articular injection. Nevertheless, MIA intra-articular injection produced specific changes in the expression of cannabinoid and opioid receptor genes in lumbar spinal cord sections that were further modulated by the genetic alteration of the cannabinoid receptor system. These results revealed that CB2 receptor plays a predominant role in the control of joint pain manifestations and is involved in the adaptive changes induced in the opioid system under this pain state.
Copyright © 2012 International Association for the Study of Pain. Published by Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23199705     DOI: 10.1016/j.pain.2012.10.009

Source DB:  PubMed          Journal:  Pain        ISSN: 0304-3959            Impact factor:   6.961


  21 in total

1.  Chronic cannabinoid receptor 2 activation reverses paclitaxel neuropathy without tolerance or cannabinoid receptor 1-dependent withdrawal.

Authors:  Liting Deng; Josée Guindon; Benjamin L Cornett; Alexandros Makriyannis; Ken Mackie; Andrea G Hohmann
Journal:  Biol Psychiatry       Date:  2014-04-25       Impact factor: 13.382

2.  Role of CB2 receptors in social and aggressive behavior in male mice.

Authors:  Marta Rodríguez-Arias; Francisco Navarrete; M Carmen Blanco-Gandia; M Carmen Arenas; María A Aguilar; Adrián Bartoll-Andrés; Olga Valverde; José Miñarro; Jorge Manzanares
Journal:  Psychopharmacology (Berl)       Date:  2015-04-29       Impact factor: 4.530

3.  Activation of the cannabinoid receptor 1 by ACEA suppresses senescence in human primary chondrocytes through sirt1 activation.

Authors:  Dawei Zhang; Gang Zhang; Zongyu Li; Bingsheng Li
Journal:  Exp Biol Med (Maywood)       Date:  2018-02-14

4.  Sigma-1 receptor modulates neuroinflammation associated with mechanical hypersensitivity and opioid tolerance in a mouse model of osteoarthritis pain.

Authors:  Mireia Carcolé; Sami Kummer; Leonor Gonçalves; Daniel Zamanillo; Manuel Merlos; Anthony H Dickenson; Begoña Fernández-Pastor; David Cabañero; Rafael Maldonado
Journal:  Br J Pharmacol       Date:  2019-09-12       Impact factor: 8.739

Review 5.  The Endogenous Cannabinoid System: A Budding Source of Targets for Treating Inflammatory and Neuropathic Pain.

Authors:  Giulia Donvito; Sara R Nass; Jenny L Wilkerson; Zachary A Curry; Lesley D Schurman; Steven G Kinsey; Aron H Lichtman
Journal:  Neuropsychopharmacology       Date:  2017-08-31       Impact factor: 7.853

Review 6.  The endocannabinoid system in pain and inflammation: Its relevance to rheumatic disease.

Authors:  Nicola Barrie; Nicholas Manolios
Journal:  Eur J Rheumatol       Date:  2017-09-01

Review 7.  Cannabinoid-hypocretin cross-talk in the central nervous system: what we know so far.

Authors:  Africa Flores; Rafael Maldonado; Fernando Berrendero
Journal:  Front Neurosci       Date:  2013-12-20       Impact factor: 4.677

Review 8.  Cannabinoid-based therapy as a future for joint degeneration. Focus on the role of CB2 receptor in the arthritis progression and pain: an updated review.

Authors:  Marta Bryk; Katarzyna Starowicz
Journal:  Pharmacol Rep       Date:  2021-05-28       Impact factor: 3.024

9.  Histone deacetylase inhibition activates Nrf2 and protects against osteoarthritis.

Authors:  Dawei Cai; Shasha Yin; Jun Yang; Qing Jiang; Wangsen Cao
Journal:  Arthritis Res Ther       Date:  2015-09-26       Impact factor: 5.156

10.  Cannabinoid CB2 receptors regulate central sensitization and pain responses associated with osteoarthritis of the knee joint.

Authors:  James J Burston; Devi Rani Sagar; Pin Shao; Mingfeng Bai; Emma King; Louis Brailsford; Jenna M Turner; Gareth J Hathway; Andrew J Bennett; David A Walsh; David A Kendall; Aron Lichtman; Victoria Chapman
Journal:  PLoS One       Date:  2013-11-25       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.